Please Note:
This profile was automatically generated using 36 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 36 references found on the Internet. This information has not been verified. Learn more...
View all 36 references Web References
-
1. www.peter.jqw.com
www.peter.jqw.com/blog_comment - [Cached]Published on: 3/5/2007 Last Visited: 5/12/2007
The key change was requiring companies looking to convert plant-based extracts into marketable prescription drugs only to purify a plant extract, which could contain hundreds of compounds, rather than pinpointing a single one. 'There were so many stories of potentially new treatments in alternative medicine ... we needed a different approach than dealing with a single small molecule,' says Shaw T. Chen, botanical team leader at the FDA. -
2. www.gordonresearch.com
www.gordonresearch.com/Present - [Cached]Published on: 3/2/2007 Last Visited: 4/1/2007
"There were so many stories of potentially new treatments in alternative medicine ... we needed a different approach than dealing with a single small molecule," says Shaw T. Chen, the botanical team leader at the FDA.
This new openness has led to a surge of applications for approvals.
...
"Overall progress has been slow," Dr. Chen says.
...
"There's a theoretical possibility that there are multiple active ingredients in botanicals that act on multiple systems that have synergistic effects," says Dr. Chen. -
3. ACMA Annual Meeting Schedule
www.acma.org/sch_annual_meetin - [Cached]Published on: 9/18/1999 Last Visited: 6/11/2008
Shaw T. Chen, M. D. , Ph. D.
...
Shaw T. Chen, M. D. , Ph. D. , Director of Renal and Cardiovascular Section, FDA
